⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-20
· read from full text
ⓘ
This 2019 study investigated whether Polycystic Ovary Syndrome elevates Cancer Antigen 125 levels in women aged 18 to 42. Researchers compared blood samples from forty participants with PCOS against a control group without the condition, measuring hormone levels and CA125 concentrations during specific follicular phases. The analysis revealed no significant difference in CA125 levels between the two groups, indicating that hormonal disturbances in non-cancerous PCOS patients do not inherently raise this tumor marker. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.
Abstract
PolyCystic Ovary Syndrome(PCOS) is an important cause of androgen excess, menstrual irregularity, and cardiometabolic dysfunction in women. iLong term manifestations such as gynaecological malignancies, like endometrial carcinoma increased to more than three folds due to endometrial hyperplasia resulting from chronic anovulation and obesity. Cancer antigen 125(CA125)glycoprotein mucin in nature tumour marker is valuable in screening for ovarian and endometrial malignancies, monitoring therapy, early detection of recurrence and, prognosis of these cancers. This study is arranged as PCOS women are considered risky group and CA125 early screening may make a change in the type of treatment..This study was done in Iraq in 2019 between July and October Forty women aged 18-42 year were included they were distributed into two groups, PCOS group, and non PCOS group. BMI was within normal for both groups. Blood samples were taken in early follicular phase for assessing luteinizing hormone (LH), follicular stimulating hormone (FSH) and free testosterone (FT) hormone. Other blood samples were taken at late follicular phase to calculate CA125levels using enzyme linked immunosorbent assay (ELISA). This study revealed no significant difference in CA125 between normal group and PCOS group .In spite of the hormonal disturbance in PCOS and increasing risk of malignancy, CA 125 was not increased in non-cancerous patients
Full text
2,051 characters
· extracted from
oa-doi-fallback
· click to expand
Polycystic Ovary Syndrome: does it Increase the Level of Cancer Antigen125?
Authors/Creators
- 1. M.B.ch.B., High Institute of Infertility, Diagnosis and Treatment/AL-Nahrain University, IRAQ / BAGHDAD
- 2. Professor Dr. High Institute of Infertility, Diagnosis and Treatment/AL-Nahrain University, IRAQ/BAGHDAD
- 3. M.B.ch. B/DOG/F.I.B.O.G. Assistant Professor Dr. High Institute of Infertility, Diagnosis and Treatment/AL-Nahrain University, IRAQ / BAGHDAD
Description
PolyCystic Ovary Syndrome(PCOS) is an important cause of androgen excess, menstrual irregularity, and cardiometabolic dysfunction in women. iLong term manifestations such as gynaecological malignancies, like endometrial carcinoma increased to more than three folds due to endometrial hyperplasia resulting from chronic anovulation and obesity. Cancer antigen 125(CA125)glycoprotein mucin in nature tumour marker is valuable in screening for ovarian and endometrial malignancies, monitoring therapy, early detection of recurrence and, prognosis of these cancers. This study is arranged as PCOS women are considered risky group and CA125 early screening may make a change in the type of treatment..This study was done in Iraq in 2019 between July and October Forty women aged 18-42 year were included they were distributed into two groups, PCOS group, and non PCOS group. BMI was within normal for both groups. Blood samples were taken in early follicular phase for assessing luteinizing hormone (LH), follicular stimulating hormone (FSH) and free testosterone (FT) hormone. Other blood samples were taken at late follicular phase to calculate CA125levels using enzyme linked immunosorbent assay (ELISA). This study revealed no significant difference in CA125 between normal group and PCOS group .In spite of the hormonal disturbance in PCOS and increasing risk of malignancy, CA 125 was not increased in non-cancerous patients
Files
Hasan et al.pdf
Files
(171.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:dc29ff9b810e26b9a450cfffe38ef85e
|
171.0 kB | Preview Download |
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.